8 results
424B5
ARCT
Arcturus Therapeutics Holdings Inc
8 Dec 20
Prospectus supplement for primary offering
5:30pm
healthy volunteer in a Phase 1 study of ARCT-810 in a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study
424B5
ARCT
Arcturus Therapeutics Holdings Inc
7 Dec 20
Prospectus supplement for primary offering
5:20pm
volunteer in a Phase 1 study of ARCT-810 in a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
10 Aug 20
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
4:22pm
-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency,
Phase 1 healthy volunteer study continues to advance … survival. The Company expects to obtain initial Phase 1 healthy volunteer study data in Q4 2020. The phase 1b study in patients has, like many other studies
424B5
ARCT
Arcturus Therapeutics Holdings Inc
30 Jul 20
Prospectus supplement for primary offering
6:01am
healthy volunteer in a Phase 1 study of ARCT-810 in a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study
424B5
trxf5gz5o zb
28 Jul 20
Prospectus supplement for primary offering
4:17pm
424B5
81z11z ro8uys
17 Apr 20
Prospectus supplement for primary offering
4:02pm
424B5
jy44v 1ap
15 Apr 20
Prospectus supplement for primary offering
4:14pm
- Prev
- 1
- Next